linjc16/ctgov huggingface dataset:
Precise Care for Cancer Related Fatigue

Study Overview
=================
Brief Summary
-----------------
This project expects to enroll 200 cancer patients and their subjective-objective measurements on fatigue, stress, symptoms, and total steps will be validated so that the information can be used in further care and improvement of life of quality of the patients.

Official Title
-----------------
Objective Data for Cancer Related Fatigue in Cancer Patients

Conditions
-----------------
Cancer-Related Condition

Intervention / Treatment
-----------------
* Behavioral: Observation for symptom distress


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Age ≧ 20 years old; One group had a cancer diagnosis, one group no cancer diagnosis; Can continuous wearing bracelet for 7 days or more Exclusion Criteria: - Unclear and unable to answer the questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Observation for symptom distress|Observation for symptom distress|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fatigue | severity of fatigue level; measurement tool: Brief Fatigue Index | 7-8 days | 
| Heart Rate Variability (HRV) monitor | Use a digital device to measure the heart rate variability and calculate the HRV data | 7-8 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distress Thermometer(DT) | a screening measure to identify and address psychological distress in individuals with cancer. a cutoff score of 3 on the DT to indicate patients with clinically elevated levels of distress. | 7-8 days | 
| Leeds Sleep Evaluation Questionnaire(LSEQ） | To assess sleep quality, higher scores mean more disrupt sleep. | 7-8 days | 
| International Physical Activity Questionnaire(IPAQ） | Life activity survey | 7-8 days | 
| Perceived Stress Scale (PSS） | higher scores mean more stressful condition | 7-8 days | 
| ESAS (Edmonton Symptom Assessment Scale) | higher scores mean more severe symptoms condition | 7-8 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer-related fatigue, smart bracelet device, symptoms for subjective and objective
Folic Acid Supplementation as an Appetizer in Primary Malnourished Egyptian Infants and Children

Study Overview
=================
Brief Summary
-----------------
Folic acid as a appetizer in primary malnutrition

Official Title
-----------------
Folic Acid Supplementation as an Appetizer in Primary Malnourished Egyptian Infants and Children

Conditions
-----------------
Primary Malnurtrition

Intervention / Treatment
-----------------
* Drug: Folic Acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary malnourished children Exclusion Criteria: previous folic supplementation in the past 3 months

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Treatment group<br> | Drug: Folic Acid<br>* Tablets<br>|
| Placebo Comparator: Control<br> | Drug: Folic Acid<br>* Tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appetite | Child eating behaviour questionnaire | Through study completion_ after 3 months from start of supplementation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leptin and ghrelin hormone | Serum level | 3 months |
Data Acquisition Study for a Communication Device for Pediatric Patients With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate a touch screen application designed to help pediatric patients with cerebral palsy communicate. The study will test how well patients type on two different tools: one tool is already on the market , and the second tool is a newly developed App.

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Device: Dynavox Maestro
* Device: Experimental App


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between the ages of 7 years old - 21 years old been diagnosed with spastic or dystonic diplegic or quadriplegic cerebral palsy. are able to communicate through written words are able to follow a 3- steps directions, and follow study directions and procedures. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dynavox Maestro and Experimental App<br>Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned. | Device: Dynavox Maestro<br>* Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.<br>Device: Experimental App<br>* Participant receives experimental app to test speed and error rate of communication.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Speed of Communication | Measure time (in minutes) to type 3 pre-set sentences | Immediately | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Error Rate of Communication | Amount of typing errors per sentence | At time of experiment |
Prognostic and Diagnostic Value of Biomarkers and Cardiac Functional Parameters in Patients With Chronic Heart Failure

Study Overview
=================
Brief Summary
-----------------
The study aims to investigate whether disease progression in patients with chronic heart failure (CHF) can be assessed by new biomarkers, and determine their diagnostic value. The study also intends to describe comparison of echocardiography with cardiopulmonary function test in CHF patients, and relating these cardiac functional parameters to clinical outcome.

Official Title
-----------------
Prognostic and Diagnostic Value of Serial Biomarker Measurements, Echocardiographic Techniques and Cardiopulmonary Function Tests in Patients With Chronic Heart Failure.

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Other: Observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years with symptoms and signs in NYHA Ⅱ Ⅳ with cardiac structural changes confirmed by echocardiography Exclusion Criteria: with other severe diseases combined and will be alive for less than 12 months hard to participate in the investigation or accept the follow-up visits pregnant or lactating women during the acute phase of ST-elevation acute myocardial infarction, stroke, severe infection and other critical conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic heart failure<br>patients who are diagnosed with chronic heart failure with either preserved or reduced ejection fraction | Other: Observational study<br> <br> * Other names: no intervention;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| main adverse cardiovascular and cerebrovascular events, MACCE | MACCE includes all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, target lesion revascularization and HF rehospitalization | 10 years | 
| cardiovascular mortality |  | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality |  | 10 years | 
| new myocardial infarction |  | 10 years | 
| new stroke |  | 10 years | 
| heart failure rehospitalization |  | 10 years | 
| quality of life | described in quality of life scores | 10 years | 
| worsening of renal function | either an increase of 0.3 mg/dl in serum creatinine or a 20% decrease in eGFR compared with baseline | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Failure, Biomarkers, Echocardiography, Cardiopulmonary Function Tests
Study of Giant Viruses of Amoebas Infections in Children Suffering From Gastroenteritis

Study Overview
=================
Brief Summary
-----------------
The discovery in 2003 by isolation of amoebas Mimivirus, the world's largest virus at the Research Unit on Tropical and Emerging Diseases in Marseille revealed fascinating information about the definition and evolution of viruses. Its genome encodes about 1,000 proteins. Three other viruses were then isolated from amoebas in this unit:Two other giant viruses, Mamavirus Marseillevirus then, and the first virus a virus, named virophage, which led to highlight the role of amoeba (Acanthamoeba spp. ) such as spawning giant viruses and compounds of bacterial origin or cellular proteins This project focuses on the detection and analysis of new viral agents (viruses and virophages giant amoeba environmental) and their involvement in human pathology. The objectives of this study are observational: detect and document the presence of giant viruses and virophages of amoebae in the faeces of children presenting to the pediatric emergency reception service of the North Hospital in AP -HM with or without clinical evidence of gastroenteritis.

Conditions
-----------------
Gastroenteritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient admitted in the Pediatric Emergency Service of Northern Hospital, Marseille, France Patient aged ≤ 15.3 years, male or female; Patient for whom a microbiological exam should be performed during the clinical management, with or without a clinical diagnosis of gastroenteritis (ie including diarrhea which will be defined by the issuance of at least three molded or watery stools per day for more than 24 hours) at the time of the collection of stool; Patient for whom informed consent was read, understood, signed by a parent or legal representative. Exclusion criteria Patient aged > 15.3 years; Patient for whom informed consent is not signed by a parent or legal representative.

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of children carriers in their digestive tract of giant viruses (and their virophages) associated with amoebae |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Giant virus, Amoeba
Evaluation of Donated Human Embryos Following in Vitro Fertilization

Study Overview
=================
Brief Summary
-----------------
Couples who have created excess embryos while undergoing IVF procedures, and who do not wish to transfer those embryos or donate them to another couple may donate the extra embryos to research. The embryos are then used to develop improved laboratory techniques and conditions as well as testing the proficiency of laboratory staff.

Detailed Description
-----------------
Undergoing IVF treatment often results in the production of more embryos than can safely be transferred at one time. These extra embryos are often cryopreserved for future use. In the event that a couple decides that they do not want to proceed with using cryopreserved embryos, these embryos can be discarded, donated to another couple, or donated to research. Embryos that are donated to research are used to identify a group of parameters that have significant predictive value for assisted reproductive technology outcomes. We hope to develop future laboratory techniques as we gain a better knowledge of gamete development, fertilization and implantation. We will test, standardize and implement better methods for freezing embryos prior to employing these techniques in a clinical setting. We hope to develop new methods to optimize the determination of genes and chromosomes in embryos. We will test the proficiency of laboratory staff on techniques and/or procedures done in the IVF laboratory. This study WILL NOT:create embryos for research, transfer embryos to an individual, develop cell lines or clones.

Official Title
-----------------
Evaluation of Donated Human Embryos for Study of Normal and Abnormal Differentiation and Development Following in Vitro Fertilization.

Conditions
-----------------
Validation of Laboratory Techniques, Validation of Laboratory Methods, Assessment of Laboratory Staff Proficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: none Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Freezing methods for embryos | To test, standardize and implement better methods for the freezing of embryos prior to these techniques being implemented in the clinical setting. | duration of the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of New Methods | The development of new methods to optimize the determination of genes and chromosomes in embryos | duration of the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Donated embryos
Quantifying Lung Tumor Movement Under Deep Inspiration Breath Holds

Study Overview
=================
Brief Summary
-----------------
Radiotherapy is a common treatment for lung cancer. One Challenge of delivering radiation treatment to lung tumors accurately is tumor movement which occurs as a patient breathes. In some situations, tumors move enough during breathing so that some or all of the tumor may be missed by a radiation treatment. One way to decrease the amount a lung tumor moves during radiotherapy treatments is for patients to held their breath briefly during a radiation treatment. By doing this, a patient's lung tumor may not move as much as it would during regular breathing. In this study, the investigators aim to study patients with lung cancers which move during breathing. Patients will be asked to hold their breath after inspiration while a CT scan of their lung tumor is obtained. The purpose of this study is to study how much less patients' lung tumors move when they hold their breath

Official Title
-----------------
Quantifying Lung Tumor Movement Under Dep Inspiration Breath Holds

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: CT scan of the chest under deep inspiration breath hold


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: biopsy confirmed primary lung cancer undergoing radiotherapy or chemoradiotherapy able to perform adequate deep inspiration breath hold patients of childbearing potential must practice adequate contraception signed study-specific informed consent form Exclusion Criteria: unable to perform adequate deep inspiration breath hold prior tumor resection prior chest or neck RT pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>single arm study | Other: CT scan of the chest under deep inspiration breath hold<br>* computed tomography scan of the chest under dep inspiration breath hold conditions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tumor movement |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer, tumor motion
QT Changes as Detected From LINQ ECG During and After Antiarrhythmic Loading (LINQ QT)

Study Overview
=================
Brief Summary
-----------------
The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.

Detailed Description
-----------------
The purpose of this study is to determine if QT interval changes are detected during and after antiarrhythmic drug loading by the designed QT detection algorithm from LINQ ECG. The QT intervals before and after antiarrhythmic loading will be compared for all patients to analyze QT changes that may be caused due to antiarrhythmic drugs.

Official Title
-----------------
Monitoring QT Intervals Using LINQ in Patients Undergoing Antiarrhythmic Drug Loading

Conditions
-----------------
Atrial Arrhythmia, QT Interval, Variation in, Arrhythmias, Cardiac

Intervention / Treatment
-----------------
* Device: LINQ/LINQ II


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients implanted with LINQ/LINQII prior to the study enrollment (no more than 50% patients implanted with LINQII), but no greater than 2.5 years for LINQ or 3.5 years for LINQII, or patients who are indicated to receive a LINQ/LINQII implant at least 7 days prior to antiarrhythmic drug loading Patients who are scheduled to receive antiarrhythmic drug loading Age 18-80 Patient is willing and able to comply with the protocol, including follow-up visits, and performing Holter recordings and patient activation transmissions Exclusion Criteria: Patients who have a contraindication to long-term antiarrhythmic therapy Patients not suitable for long-term antiarrhythmic therapy Patients with a previous, existing cardiac implantation (i.e., cardiac pacemaker or cardiac resynchronization requiring > 40% pacing, implantable cardioverter defibrillator (ICDs)) Patients with permanent and persistent AF Co-enrollment in another study or planning to participate in a concurrent device study during the course of this clinical study that could confound the results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: LINQ/LINQ II|Algorithm developed and validated to continuously measure QT intervals for every beat using LINQ/LINQ II ECG. This study is aimed at determining if QT interval changes can be detected during and after antiarrhythmic drug loading by the designed QT detection algorithm from LINQ/LINQ II ECG.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QT intervals before and after antiarrhythmic loading | The QT intervals before and after antiarrhythmic loading will be compared for all patients to analyze QT changes that may be caused due to antiarrhythmic drugs. | 90 days |
Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2

Study Overview
=================
Brief Summary
-----------------
This study will evaluate if periodontal mechanical treatment is capable to alter immunological and genetical parameters related to systemic health in patients with chronic periodontitis ant diabetes type 2.

Official Title
-----------------
Effect of Mechanical Periodontal Therapy in the Microbiological, Immunocellular and Immunoglobulin Profiles and in the Dosage of Pro and Anti-inflammatory Cytokines From Peripheral Blood and Saliva of Subjects With Chronic Periodontitis and Diabetes Type 2

Conditions
-----------------
Chronic Periodontitis, Diabetes Type 2

Intervention / Treatment
-----------------
* Device: Mechanical periodontal therapy
* Procedure: nonsurgical periodontal therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Periodontitis group: Minimum of 15 teeh; At least 30% of sites with periodontal probing depth ≥ 4 mm and at least two teeth with CAL ≥ 3 mm; Age ≥30 years; Control group: Systemically healthy; 20 teeth; Probing depth ≤3 mm, clinical attachment level ≤3 mm , ≤10% of sites with bleeding on probing. Exclusion Criteria: Periodontal treatment in the last six months; Continued use of medications such as antibiotics, immunomodulatory, anti-inflammatory drugs or corticosteroids in the last three months; Systemic diseases that interfere with periodontal condition, except for diabetes for the test group (HIV, cancer, immune disorders, acute infections, severe allergies, gastrointestinal or kidney disease, morbid obesity [BMI 40 kg / m2] or underweight [evil nourished BMI <18.5 kg / m2], etc.); Pregnant or lactating; smoking; Age <30 years; Indigenous groups.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| root planning<br> | Device: Mechanical periodontal therapy<br> <br> * Other names: periodontal debridment;Procedure: nonsurgical periodontal therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of alteration in periodontal pathogens by PCR | Evaluate wich periodontal pathogens are detected before and after treatment | One year | 
| Evidence of alteration of immunocellular response by flowcytometry | Fenotype Monocytes, PMN, NK cells, T cells, B cells before and after periodontal treatment | one year | 
| Evidence of alteration on pro and anti-inflammatory cytokines by CBA | Dosage of cytokines before and after periodontal treatment | One year |